169 related articles for article (PubMed ID: 36893945)
21. Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcoma.
Akin S; Dizdar O; Karakas Y; Turker A; Kars A
Curr Probl Cancer; 2018; 42(3):344-349. PubMed ID: 29576383
[TBL] [Abstract][Full Text] [Related]
22.
Seligson ND; Kautto EA; Passen EN; Stets C; Toland AE; Millis SZ; Meyer CF; Hays JL; Chen JL
Oncologist; 2019 Jul; 24(7):973-979. PubMed ID: 30541756
[TBL] [Abstract][Full Text] [Related]
23. Novel approaches to treatment of leiomyosarcomas.
Collins IM; Thomas DM
Curr Oncol Rep; 2011 Aug; 13(4):316-22. PubMed ID: 21503594
[TBL] [Abstract][Full Text] [Related]
24. Bcl-2 receptor expression in patients with uterine smooth muscle tumors: an immunohistochemical analysis comparing leiomyoma, uterine smooth muscle tumor of uncertain malignant potential, and leiomyosarcoma.
Bodner K; Bodner-Adler B; Kimberger O; Czerwenka K; Mayerhofer K
J Soc Gynecol Investig; 2004 Apr; 11(3):187-91. PubMed ID: 15051039
[TBL] [Abstract][Full Text] [Related]
25. Molecular biomarkers for uterine leiomyosarcoma and endometrial stromal sarcoma.
Tsuyoshi H; Yoshida Y
Cancer Sci; 2018 Jun; 109(6):1743-1752. PubMed ID: 29660202
[TBL] [Abstract][Full Text] [Related]
26. Uterine leiomyosarcoma: a review article.
Gockley AA; Rauh-Hain JA; del Carmen MG
Int J Gynecol Cancer; 2014 Nov; 24(9):1538-42. PubMed ID: 25304676
[TBL] [Abstract][Full Text] [Related]
27. Relationships between highly recurrent tumor suppressor alterations in 489 leiomyosarcomas.
Schaefer IM; Lundberg MZ; Demicco EG; Przybyl J; Matusiak M; Chibon F; Ingram DR; Hornick JL; Wang WL; Bauer S; Baker LH; Lazar AJ; van de Rijn M; Mariño-Enríquez A; Fletcher JA
Cancer; 2021 Aug; 127(15):2666-2673. PubMed ID: 33788262
[TBL] [Abstract][Full Text] [Related]
28. Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial.
Pautier P; Italiano A; Piperno-Neumann S; Chevreau C; Penel N; Firmin N; Boudou-Rouquette P; Bertucci F; Balleyguier C; Lebrun-Ly V; Ray-Coquard I; Kalbacher E; Bardet A; Bompas E; Collard O; Isambert N; Guillemet C; Rios M; Archambaud B; Duffaud F;
Lancet Oncol; 2022 Aug; 23(8):1044-1054. PubMed ID: 35835135
[TBL] [Abstract][Full Text] [Related]
29. Analysis of clinicopathologic prognostic factors for 157 uterine sarcomas and evaluation of a grading score validated for soft tissue sarcoma.
Pautier P; Genestie C; Rey A; Morice P; Roche B; Lhommé C; Haie-Meder C; Duvillard P
Cancer; 2000 Mar; 88(6):1425-31. PubMed ID: 10717626
[TBL] [Abstract][Full Text] [Related]
30. [Clinicopathologic characteristics and prognosis factors of uterine sarcomas in central Tunisia].
Khlifi A; Fathallah K; Zbidi C; Hidar S; Bibi M; Khairi H
Bull Cancer; 2014; 101(7-8):669-80. PubMed ID: 25091649
[TBL] [Abstract][Full Text] [Related]
31. Mesna, doxorubicin, ifosfamide and dacarbazine chemotherapy for uterine leiomyosarcoma: a report of two cases.
Minobe S; Todo Y; Suzuki Y; Aoyagi Y; Umazume T; Okamoto K; Kato H
J Obstet Gynaecol Res; 2011 Jun; 37(6):645-9. PubMed ID: 21375676
[TBL] [Abstract][Full Text] [Related]
32. Uterine leiomyosarcoma and endometrial stromal sarcoma: lymph node metastases and sites of recurrence.
Goff BA; Rice LW; Fleischhacker D; Muntz HG; Falkenberry SS; Nikrui N; Fuller AF
Gynecol Oncol; 1993 Jul; 50(1):105-9. PubMed ID: 8349151
[TBL] [Abstract][Full Text] [Related]
33. Histology-driven chemotherapy in soft tissue sarcomas.
Scurr M
Curr Treat Options Oncol; 2011 Mar; 12(1):32-45. PubMed ID: 21359911
[TBL] [Abstract][Full Text] [Related]
34. [Chemotherapy and hormone therapy for uterine sarcomas].
Yamashita H; Arai H; Aoki D
Gan To Kagaku Ryoho; 2012 May; 39(5):722-5. PubMed ID: 22584323
[TBL] [Abstract][Full Text] [Related]
35. Outcome of uterine sarcoma patients treated with pazopanib: A retrospective analysis based on two European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG) clinical trials 62043 and 62072.
Benson C; Ray-Coquard I; Sleijfer S; Litière S; Blay JY; Le Cesne A; Papai Z; Judson I; Schöffski P; Chawla S; Gil T; Piperno-Neumann S; Marréaud S; Dewji MR; van der Graaf WTA
Gynecol Oncol; 2016 Jul; 142(1):89-94. PubMed ID: 27012429
[TBL] [Abstract][Full Text] [Related]
36. Options for Adjuvant Therapy for Uterine Leiomyosarcoma.
Friedman CF; Hensley ML
Curr Treat Options Oncol; 2018 Feb; 19(2):7. PubMed ID: 29417238
[TBL] [Abstract][Full Text] [Related]
37. [Chemotherapy options for patients with advanced soft-tissue sarcoma beyond anthracyclines].
Italiano A; Toulmonde M; Bui-Nguyen B
Bull Cancer; 2010 Jun; 97(6):679-86. PubMed ID: 20483708
[TBL] [Abstract][Full Text] [Related]
38. Efficacy thresholds for clinical trials with advanced or metastatic leiomyosarcoma patients: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group meta-analysis based on a literature review for soft-tissue sarcomas.
Kantidakis G; Litière S; Neven A; Vinches M; Judson I; Schöffski P; Wardelmann E; Stacchiotti S; D'Ambrosio L; Marréaud S; van der Graaf WTA; Kasper B; Fiocco M; Gelderblom H
Eur J Cancer; 2021 Sep; 154():253-268. PubMed ID: 34298376
[TBL] [Abstract][Full Text] [Related]
39. [Uterine leiomyosarcoma - French guidelines from the GSF/NETSARC and TMRG groups].
Collineau B; Genestie C; Croce S; Meeus P; Floquet A; Guyon F; Llacer-Moscardo C; Lebreton C; Taieb S; Toulmonde M; Blay JY; Bonvalot S; Ray-Coquard I; Pautier P; Duffaud F
Bull Cancer; 2023 Apr; 110(4):440-449. PubMed ID: 36863922
[TBL] [Abstract][Full Text] [Related]
40. Trends in the treatment of uterine leiomyosarcoma in the Medicare population.
Foley OW; Rauh-Hain JA; Clemmer J; Clark RM; Hall T; Diver EJ; Schorge JO; del Carmen MG
Int J Gynecol Cancer; 2015 Mar; 25(3):453-8. PubMed ID: 25628107
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]